Cargando…
Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial
Master protocol designs allow for simultaneous comparison of multiple treatments or disease subgroups. Master protocols can also be designed as seamless studies, in which two or more clinical phases are considered within the same trial. They can be divided into two categories: operationally seamless...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521165/ https://www.ncbi.nlm.nih.gov/pubmed/36919403 http://dx.doi.org/10.1177/09622802231160554 |
_version_ | 1785110075154628608 |
---|---|
author | Duputel, Benjamin Stallard, Nigel Montestruc, François Zohar, Sarah Ursino, Moreno |
author_facet | Duputel, Benjamin Stallard, Nigel Montestruc, François Zohar, Sarah Ursino, Moreno |
author_sort | Duputel, Benjamin |
collection | PubMed |
description | Master protocol designs allow for simultaneous comparison of multiple treatments or disease subgroups. Master protocols can also be designed as seamless studies, in which two or more clinical phases are considered within the same trial. They can be divided into two categories: operationally seamless, in which the two phases are separated into two independent studies, and inferentially seamless, in which the interim analysis is considered an adaptation of the study. Bayesian designs are scarcely studied. Our aim is to propose and compare Bayesian operationally seamless Phase II/III designs using a binary endpoint for the first stage and a time-to-event endpoint for the second stage. At the end of Phase II, arm selection is based on posterior (futility) and predictive (selection) probabilities. The results of the first phase are then incorporated into prior distributions of a time-to-event model. Simulation studies showed that Bayesian operationally seamless designs can approach the inferentially seamless counterpart, allowing for an increasing simulated power with respect to the operationally frequentist design. |
format | Online Article Text |
id | pubmed-10521165 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-105211652023-09-27 Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial Duputel, Benjamin Stallard, Nigel Montestruc, François Zohar, Sarah Ursino, Moreno Stat Methods Med Res Original Research Articles Master protocol designs allow for simultaneous comparison of multiple treatments or disease subgroups. Master protocols can also be designed as seamless studies, in which two or more clinical phases are considered within the same trial. They can be divided into two categories: operationally seamless, in which the two phases are separated into two independent studies, and inferentially seamless, in which the interim analysis is considered an adaptation of the study. Bayesian designs are scarcely studied. Our aim is to propose and compare Bayesian operationally seamless Phase II/III designs using a binary endpoint for the first stage and a time-to-event endpoint for the second stage. At the end of Phase II, arm selection is based on posterior (futility) and predictive (selection) probabilities. The results of the first phase are then incorporated into prior distributions of a time-to-event model. Simulation studies showed that Bayesian operationally seamless designs can approach the inferentially seamless counterpart, allowing for an increasing simulated power with respect to the operationally frequentist design. SAGE Publications 2023-03-15 2023-05 /pmc/articles/PMC10521165/ /pubmed/36919403 http://dx.doi.org/10.1177/09622802231160554 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Articles Duputel, Benjamin Stallard, Nigel Montestruc, François Zohar, Sarah Ursino, Moreno Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial |
title | Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial |
title_full | Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial |
title_fullStr | Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial |
title_full_unstemmed | Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial |
title_short | Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial |
title_sort | using dichotomized survival data to construct a prior distribution for a bayesian seamless phase ii/iii clinical trial |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521165/ https://www.ncbi.nlm.nih.gov/pubmed/36919403 http://dx.doi.org/10.1177/09622802231160554 |
work_keys_str_mv | AT duputelbenjamin usingdichotomizedsurvivaldatatoconstructapriordistributionforabayesianseamlessphaseiiiiiclinicaltrial AT stallardnigel usingdichotomizedsurvivaldatatoconstructapriordistributionforabayesianseamlessphaseiiiiiclinicaltrial AT montestrucfrancois usingdichotomizedsurvivaldatatoconstructapriordistributionforabayesianseamlessphaseiiiiiclinicaltrial AT zoharsarah usingdichotomizedsurvivaldatatoconstructapriordistributionforabayesianseamlessphaseiiiiiclinicaltrial AT ursinomoreno usingdichotomizedsurvivaldatatoconstructapriordistributionforabayesianseamlessphaseiiiiiclinicaltrial |